MCL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In line with these observations, we noted that the combination of MCL1 inhibition and TKI therapy exerted strong synergistic antitumorigenic effects on CML stem/progenitor cells, both in the absence or presence of these cytokines.